Abstract
Purpose: In EPHESUS, eplerenone (EPL) significantly decreased the risk of hospitalization for heart failure (HF) versus placebo (PBO) when added to standard HF treatment in patients with left ventricular dysfunction (LVD) and signs of HF after acute myocardial infarction (AMI). Because HF hospitalization is a major morbid event for HF patients, we retrospectively evaluated the effect of EPL added to standard HF treatment on the composite endpoint of time to all-cause mortality or HF hospitalization in high-risk subgroups and determined the risk of death in patients hospitalized for HF.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
